ScripsAmerica Inc., New Castle, a supplier of over the counter and other drugs, announced that the company has signed an agreement with Capricorn Pharma, Inc., Frederick, Md. for the development, manufacturing and supply of its RapiMed children’s pain reliever and fever reducer.
CPI will manufacture and distribute ScripsAmerica’s RapiMed dissolvable pain relief remedy in 80 mg and 160 mg tablets, including cherry and grape flavors.
The initial term of the contract is two years with two five-year extension options and include distribution within the U.S. and North America.
CPI will manufacture and distribute a minimum of 20 million tablets with both parties expecting production to increase each year, leading to a projected volume of approximately 97 million RapiMed tablets being distributed in the agreement’s seventh year.
ScripsAmerica anticipates launching its RapiMed product in September of this year into retail, food and drug store chains with plans to expand its distribution avenues.
CEO of ScripsAmerica, Bob Schneiderman, commented, “This is an exciting and important development for the company as we prepare for our anticipated RapiMed product launch later this year. CPI is a very reputable manufacturer in the generic drug market and we are confident that our relationship will be very productive and beneficial for ScripsAmerica and its shareholders.”
